[1]
|
屈泽超, 王栋, 冯铭哲, 等. 破骨细胞分化信号传导及相关天然化合物的研究进展[J]. 中国骨质疏松杂志, 2023, 29(2): 282-287 296.
|
[2]
|
中华医学会骨科学分会. 骨质疏松性骨折诊疗指南(2022年版) [J]. 中华骨科杂志, 2022, 42(22): 1473-1491.
|
[3]
|
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017) [J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(5): 413-443.
|
[4]
|
Chang, X., Xu, S. and Zhang, H. (2022) Regulation of Bone Health through Physical Exercise: Mechanisms and Types. Frontiers in Endocrinology (Lausanne), 13, Article ID: 1029475. https://doi.org/10.3389/fendo.2022.1029475
|
[5]
|
《中国骨质疏松杂志》社, 《中国骨质疏松杂志》骨代谢专家组. 骨质疏松分子生物学研究专家共识[J/OL]. 中国骨质疏松杂志. https://link.cnki.net/urlid/11.3701.r.20231201.1403.002, 2023-12-01.
|
[6]
|
Li, S.S., He, S.H., Xie, P.Y., et al. (2021) Recent Progresses in the Treatment of Osteoporosis. Frontiers in Pharmacology, 12, Article No. 16. https://doi.org/10.3389/fphar.2021.717065
|
[7]
|
Galeone, A., Grano, M. and Brunetti, G. (2023) Tumor Necrosis Factor Family Members and Myocardial Ischemia-Reperfusion Injury: State of the Art and Therapeutic Implications. International Journal of Molecular Sciences, 24, Article No. 4606. https://doi.org/10.3390/ijms24054606
|
[8]
|
Udagawa, N., Koide, M., Nakamura, M., et al. (2021) Osteoclast Differentiation by RANKL and OPG Signaling Pathways. Journal of Bone and Mineral Metabolism, 39, 19-26. https://doi.org/10.1007/s00774-020-01162-6
|
[9]
|
Takegahara, N., Kim, H. and Choi, Y. (2022) RANKL Biology. Bone, 159, Article ID: 116353. https://doi.org/10.1016/j.bone.2022.116353
|
[10]
|
Cannata-Andia, J.B., Carrillo-Lopez, N., Messina, O.D., et al. (2021) Pathophysiology of Vascular Calcification and Bone Loss: Linked Disorders of Ageing? Nutrients, 13, Article No. 3835. https://doi.org/10.3390/nu13113835
|
[11]
|
Zhang, L., Zeng, F., Jiang, M., et al. (2022) Roles of Osteoprotegerin in Endocrine and Metabolic Disorders through Receptor Activator of Nuclear Factor Kappa-B Ligand/Receptor Activator of Nuclear Factor Kappa-B Signaling. Frontiers in Cell and Developmental Biology, 10, Article ID: 1005681. https://doi.org/10.3389/fcell.2022.1005681
|
[12]
|
赵常红, 李世昌, 李沛鸿, 等. 调节破骨细胞功能的相关信号分子的研究进展[J]. 中国骨质疏松杂志, 2021, 27(9): 1361-1365.
|
[13]
|
陈浩然, 于冬冬, 齐鹏坤, 等. 基于OPG/RANKL/RANK信号通路治疗绝经后骨质疏松症中西医研究进展[J]. 辽宁中医药大学学报, 2022, 24(7): 179-183.
|
[14]
|
金健, 金大地. 利塞膦酸钠抑制大鼠骨髓内脂肪细胞分化及脂肪细胞核因子κB受体活化因子配体蛋白的表达[J]. 南方医科大学学报, 2019, 39(8): 987-992.
|
[15]
|
钟亚春, 陆璇, 徐立. 利塞膦酸钠和阿仑膦酸钠治疗对股骨粗隆下侧皮质骨密度变化的影响对比研究[J]. 中国骨质疏松杂志, 2019, 25(6): 842-846.
|
[16]
|
Compston, J.E., Mcclung, M.R. and Leslie, W.D. (2019) Osteoporosis. The Lancet, 393, 364-376. https://doi.org/10.1016/S0140-6736(18)32112-3
|
[17]
|
Anastasilakis, A.D., Makras, P., Yavropoulou, M.P., et al. (2021) Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. Journal of Clinical Medicine, 10, Article No. 152. https://doi.org/10.3390/jcm10010152
|
[18]
|
Anastasilakis, A.D., Papapoulos, S.E., Polyzos, S.A., et al. (2019) Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial. Journal of Bone and Mineral Research, 34, 2220-2228. https://doi.org/10.1002/jbmr.3853
|
[19]
|
Nakai, Y., Okamoto, K., Terashima, A., et al. (2019) Efficacy of an Orally Active Small-Molecule Inhibitor of RANKL in Bone Metastasis. Bone Research, 7, Article No. 1. https://doi.org/10.1038/s41413-018-0036-5
|
[20]
|
Liang, B., Burley, G., Lin, S., et al. (2022) Osteoporosis Pathogenesis and Treatment: Existing and Emerging Avenues. Cellular & Molecular Biology Letters, 27, Article No. 72. https://doi.org/10.1186/s11658-022-00371-3
|
[21]
|
陈桐莹. 基于Wnt/β-Catenin信号通路研究肉苁蓉苷A调控成骨细胞自噬的机制[D]: [硕士学位论文]. 广州: 广州中医药大学, 2021.
|
[22]
|
郭一览, 孙朋. Wnt/β-Catenin信号通路在运动调控骨形成中的机制[J]. 生命科学, 2022, 34(12): 1519-1529.
|
[23]
|
丁小芬, 周友龙, 田明月, 等. Wnt/β-Catenin信号通路与膝关节骨性关节炎软骨代谢[J]. 中国老年学杂志, 2022, 42(23): 5917-5921.
|
[24]
|
万冰莹, 陈岱. 慢性肾脏病矿物质及骨代谢紊乱的研究进展[J]. 实用中医内科杂志, 2022, 36(8): 68-75.
|
[25]
|
褚赞波, 邹荣鑫, 黄海燕, 等. 破骨细胞功能调控与骨吸收抑制剂[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(5): 509-514.
|
[26]
|
陈文文, 孙雯雯, 尹玲, 等. 新型骨硬化蛋白抑制剂Romosozumab在骨质疏松症治疗中的应用: 从临床试验到临床应用[J]. 中国医院药学杂志, 2021, 41(1): 115-118.
|
[27]
|
Mcclung, M.R., Grauer, A., Boonen, S., et al. (2014) Romosozumab in Postmenopausal Women with Low Bone Mineral Density. The New England Journal of Medicine, 370, 412-420. https://doi.org/10.1056/NEJMoa1305224
|
[28]
|
Fixen, C. and Tunoa, J. (2021) Romosozumab: A Review of Efficacy, Safety, and Cardiovascular Risk. Current Osteoporosis Reports, 19, 15-22. https://doi.org/10.1007/s11914-020-00652-w
|
[29]
|
Recknor, C.P., Recker, R.R., Benson, C.T., et al. (2015) The Effect of Discontinuing Treatment with Blosozumab: Follow-Up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women with Low Bone Mineral Density. Journal of Bone and Mineral Research, 30, 1717-1725. https://doi.org/10.1002/jbmr.2489
|
[30]
|
Van Dinther, M., Zhang, J., Weidauer, S.E., et al. (2013) Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling. PLOS ONE, 8, E62295. https://doi.org/10.1371/journal.pone.0062295
|
[31]
|
Boschert, V., Van Dinther, M., Weidauer, S., et al. (2013) Mutational Analysis of Sclerostin Shows Importance of the Flexible Loop and the Cystine-Knot for Wnt-Signaling Inhibition. PLOS ONE, 8, E81710. https://doi.org/10.1371/journal.pone.0081710
|
[32]
|
Mijanovic, O., Jakovleva, A., Brankovic, A., et al. (2022) Cathepsin K in Pathological Conditions and New Therapeutic and Diagnostic Perspectives. International Journal of Molecular Sciences, 23, Article No. 13762. https://doi.org/10.3390/ijms232213762
|
[33]
|
Mukherjee, K. and Chattopadhyay, N. (2016) Pharmacological Inhibition of Cathepsin K: A Promising Novel Approach for Postmenopausal Osteoporosis Therapy. Biochemical Pharmacology, 117, 10-19. https://doi.org/10.1016/j.bcp.2016.04.010
|
[34]
|
Lotinun, S., Kiviranta, R., Matsubara, T., et al. (2013) Osteoclast-Specific Cathepsin K Deletion Stimulates S1P-Dependent Bone Formation. Journal of Clinical Investigation, 123, 666-681. https://doi.org/10.1172/JCI64840
|
[35]
|
Stone, J.A., Mccrea, J.B., Witter, R., et al. (2019) Clinical and Translational Pharmacology of the Cathepsin K Inhibitor Odanacatib Studied for Osteoporosis. British Journal of Clinical Pharmacology, 85, 1072-1083. https://doi.org/10.1111/bcp.13869
|
[36]
|
Jensen, P.R., Andersen, T.L., Pennypacker, B.L., et al. (2014) The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits. Calcified Tissue International, 94, 212-222. https://doi.org/10.1007/s00223-013-9800-0
|
[37]
|
Bone, H.G., Mcclung, M.R., Roux, C., et al. (2010) Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women with Low Bone Density. Journal of Bone and Mineral Research, 25, 937-947. https://doi.org/10.1359/jbmr.091035
|
[38]
|
Chapurlat, R.D. (2015) Odanacatib: A Review of Its Potential in the Management of Osteoporosis in Postmenopausal Women. Therapeutic Advances in Musculoskeletal Disease, 7, 103-109. https://doi.org/10.1177/1759720X15580903
|
[39]
|
Jerome, C., Missbach, M. and Gamse, R. (2012) Balicatib, a Cathepsin K Inhibitor, Stimulates Periosteal Bone Formation in Monkeys. Osteoporosis International, 23, 339-349. https://doi.org/10.1007/s00198-011-1593-2
|
[40]
|
Runger, T.M., Adami, S., Benhamou, C.L., et al. (2012) Morphea-Like Skin Reactions in Patients Treated with the Cathepsin K Inhibitor Balicatib. Journal of the American Academy of Dermatology, 66, E89-E96. https://doi.org/10.1016/j.jaad.2010.11.033
|